207 related articles for article (PubMed ID: 28196490)
1. Rechallenge and maintenance therapy using cetuximab and chemotherapy administered to a patient with metastatic colorectal cancer.
Ma J; Yang QL; Ling Y
BMC Cancer; 2017 Feb; 17(1):132. PubMed ID: 28196490
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
3. Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.
Huang MY; Chen MJ; Tsai HL; Kuo CH; Ma CJ; Hou MF; Chuang SC; Lin SR; Wang JY
Genet Mol Res; 2011 Oct; 10(4):3002-12. PubMed ID: 21968808
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E
Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966
[TBL] [Abstract][Full Text] [Related]
5. The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer.
Jia J; Zhang P; Gou M; Yang F; Qian N; Dai G
Dis Markers; 2019; 2019():6812045. PubMed ID: 30805037
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer.
Spigel DR; Greco FA; Waterhouse D; Shipley D; Lane CM; Vazquez ER; Clark BL; Infante JR; Bendell JC; Burris HA; Hainsworth JD
Clin Adv Hematol Oncol; 2010 Jul; 8(7):480-5, 498. PubMed ID: 20864916
[TBL] [Abstract][Full Text] [Related]
7. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
Soda H; Maeda H; Hasegawa J; Takahashi T; Hazama S; Fukunaga M; Kono E; Kotaka M; Sakamoto J; Nagata N; Oba K; Mishima H
BMC Cancer; 2015 Oct; 15():695. PubMed ID: 26467662
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?
Bertocchi P; Aroldi F; Prochilo T; Meriggi F; Beretta GD; Zaniboni A
J Chemother; 2017 Apr; 29(2):102-105. PubMed ID: 28032528
[TBL] [Abstract][Full Text] [Related]
9. FOLFOX plus cetuximab for a patient with metastatic colorectal cancer with icterus due to multiple liver metastases.
Mizota A; Shitara K; Kondo C; Nomura M; Yokota T; Takahari D; Ura T; Muro K
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1205-8. PubMed ID: 21772113
[TBL] [Abstract][Full Text] [Related]
10. Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group.
Pfeiffer P; Sorbye H; Qvortrup C; Karlberg M; Kersten C; Vistisen K; Lindh B; Bjerregaard JK; Glimelius B
Clin Colorectal Cancer; 2015 Sep; 14(3):170-6. PubMed ID: 25956187
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
12. [A case of multiple lung and liver metastases from colon cancer treated with clinical benefit by hepatic arterial infusion chemotherapy plus cetuximab mono-therapy after standard chemotherapy failure].
Osawa G; Yoshimatsu K; Yokomizo H; Otani T; Yano Y; Itagaki H; Matsumoto A; Fujimoto T; Umehara A; Ogawa K
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2526-8. PubMed ID: 21224628
[TBL] [Abstract][Full Text] [Related]
13. A case of heterogeneous sensitivity to panitumumab in cetuximab-refractory colorectal adenocarcinoma metastases.
Marks E; Rizvi SM; Sarwani N; Yang Z; El-Deiry WS
Cancer Biol Ther; 2015; 16(3):377-82. PubMed ID: 25695537
[TBL] [Abstract][Full Text] [Related]
14. Recurrent disease four years after surgery and adjuvant chemotherapy.
Pozzo C; Barone C
Cancer Treat Rev; 2008; 34 Suppl 2():S8-11. PubMed ID: 19101406
[TBL] [Abstract][Full Text] [Related]
15. [Cetuximab-associated skin ulceration in patient with metastatic colorectal cancer: a case report].
Tsuboi K; Kawase Y; Okochi O; Hattori M; Takami Y; Takeda S; Mizuno A; Sato Y; Uno Y; Hayashi T; Sasada Y; Takamura S; Kozaki K
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1549-52. PubMed ID: 21918361
[TBL] [Abstract][Full Text] [Related]
16. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
[TBL] [Abstract][Full Text] [Related]
17. [A case of colon cancer with multiple liver metastases responding ot S-1 as third-line treatment following FOLFIRI and FOLFOX].
Miyahira T; Teruya N; Matsuura F; Murayama S; Aka H; Teruya J; Hanashiro N; Nishihara M; Okushima N; Toda Y; Kiyuna M
Gan To Kagaku Ryoho; 2010 Feb; 37(2):331-4. PubMed ID: 20210032
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer.
Inoue Y; Hazama S; Suzuki N; Tokumitsu Y; Kanekiyo S; Tomochika S; Tsunedomi R; Tokuhisa Y; Iida M; Sakamoto K; Takeda S; Ueno T; Yoshino S; Nagano H
Cancer Sci; 2017 Mar; 108(3):455-460. PubMed ID: 28075526
[TBL] [Abstract][Full Text] [Related]
19. [Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].
Li YH; An X; Xiang XJ; Wang ZQ; Wang FH; Feng F; Jiang WQ; He YJ; Xu RH
Ai Zheng; 2009 Sep; 28(9):939-44. PubMed ID: 19728911
[TBL] [Abstract][Full Text] [Related]
20. Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.
Fornaro L; Vasile E; Masi G; Loupakis F; Baldi GG; Allegrini G; Salvatore L; Cremolini C; Cupini S; Cortesi E; Tuzi A; Granetto C; Brunetti IM; Ricci S; Falcone A
Clin Colorectal Cancer; 2012 Mar; 11(1):71-6. PubMed ID: 21903485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
